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Oncogenic mutations in the small GTPase Ras are
highly prevalent in cancer, but an understanding of
the vulnerabilities of these cancers is lacking. We
undertook a genome-wide RNAi screen to identify
synthetic lethal interactions with the KRAS onco-
gene. We discovered a diverse set of proteins whose
depletion selectively impaired the viability of Ras
mutant cells. Among these we observed a strong
enrichment for genes with mitotic functions. We
describe a pathway involving the mitotic kinase
PLK1, the anaphase-promoting complex/cyclosome,
and the proteasome that, when inhibited, results in
prometaphase accumulation and the subsequent
death of Ras mutant cells. Gene expression analysis
indicates that reduced expression of genes in this
pathway correlates with increased survival of
patients bearing tumors with a Ras transcriptional
signature. Our results suggest a previously underap-
preciated role for Ras in mitotic progression and
demonstrate a pharmacologically tractable pathway
for the potential treatment of cancers harboring Ras
mutations.
INTRODUCTION
A major challenge in cancer therapeutics is the identification of
cellular drug targets whose inhibition leads to the selective killing
of cancer cells while sparing normal cells. Recent advances in
mammalian RNA interference (RNAi) technologies have made it
possible to systematically interrogate the human genome for
genes whose loss of function constitutes synthetic lethality either
with the oncogenic state or with particular oncogenic mutations(Ngo et al., 2006; Schlabach et al., 2008; Silva et al., 2008). We
have developed barcoded, retroviral/lentiviral-based short
hairpin RNA (shRNA) libraries targeting the entire human genome
to enable genome-wide loss-of-function analysis through stable
gene knockdown (Silva et al., 2005). Our design also allowed
us to use microarray deconvolution to develop a multiplex
screening platform that enables the highly parallel screening
of >10,000 shRNAs in a pool-based format (Schlabach et al.,
2008; Silva et al., 2008). These technological breakthroughs
have made it possible to rapidly interrogate the genome for func-
tional vulnerability of cancer cells and here we apply these to the
Ras oncogene.
The Ras family of small GTPases are frequently mutated in
human cancers (reviewed in Karnoub and Weinberg, 2008). Ras
is a membrane-bound signaling molecule that cycles between
the inactive, GDP-bound state and the active, GTP-bound state.
Growth factor receptor signaling promotes GTP loading and
activation of Ras, which in turn activates an array of downstream
pathways to promote cell proliferation and survival. Among
the major Ras effector pathways is the MAP kinase pathway,
the PI3-kinase (PI3K) pathway, RalGDS proteins, phospholi-
pase-C3, and Rac. Each of these has been implicated in media-
tion of Ras oncogenesis. Ras GAPs (GTPase-activating proteins)
inactivate Ras by stimulating GTP hydrolysis. Oncogenic muta-
tions in Ras are invariably point mutations that either interfere
with Ras GAP binding or directly disrupt Ras GTPase activity,
locking Ras in a constitutively active, GTP-bound state. Onco-
genic mutations have been found in all three members of the
Ras gene family with KRAS being the most frequently mutated.
KRAS mutations are found at high frequencies in pancreatic,
thyroid, colon, lung, and liver cancers and in myelodyspastic
syndrome and are correlated with poor prognosis (Karnoub and
Weinberg, 2008).
Despite its prominent status as a cancer drug target, thera-
peutics aimed at disrupting the Ras pathway have proven chal-
lenging thus far. Inhibitors of farnesyl transferase, the enzymeCell 137, 835–848, May 29, 2009 ª2009 Elsevier Inc. 835
that prenylates Ras for its membrane localization, have met with
only limited success (Karnoub and Weinberg, 2008). Chemical
screens in isogenic Ras mutant and wild-type cell lines have
identified compounds that exhibit preferential toxicity toward
Ras mutant cells (Torrance et al., 2001; Dolma et al., 2003).
However, the translation of these chemical screens into clinical
practice has been impeded by the challenge in identifying the
protein targets of these chemical entities and subsequent drug
development. Inhibitors targeting various Ras effecter pathways
could also prove efficacious in treating tumors with Ras muta-
tions, as it was recently shown that a combined application of
MEK and PI3K/mTOR inhibitors can reduce tumor burden in
a mouse model of Ras-driven lung cancer (Engelman et al.,
2008). However, the prevalence of de novo and acquired drug
resistance to other targeted therapies suggests that combina-
tions of multiple therapeutic agents will be required to effectively
inhibit malignant progression.
In principle, tumors can be attacked either by reversing the
effects of oncoproteins through inhibition (i.e., exploiting onco-
gene addiction) or by attacking tumor-specific vulnerabilities
caused by the oncogenic state, often by inhibiting proteins that
are not oncoproteins themselves (i.e., exploiting nononcogene
addiction) (Solimini et al., 2007; Luo et al., 2009). The inappro-
priate rewiring of cellular signaling through oncogene activation
should result in vulnerabilities that could be exploited for cancer
therapies in theory. Since these vulnerabilities are not obvious
and cannot be predicted, the most direct approach to their
discovery is through genetic exploration. The systematic identi-
fication of genes and pathways necessary for the Ras-driven
oncogenic state would provide additional drug targets for thera-
peutic exploration, shed new light on Ras’ mechanisms of
action, and potentially provide new biomarkers for patient strat-
ification. To this end, we screened our shRNA library for genes
whose inhibition constitutes synthetic lethality with the KRAS
oncogene. We identified a functionally diverse set of genes
including a number of mitotic proteins and demonstrate that
pharmacological inhibitors targeting these mitotic proteins can
selectively impair the viability of Ras mutant cells. These findings
point to a previously underappreciated role of Ras in mitotic
progression and demonstrate that mitotic stress induced by
the Ras oncogene might be exploited for therapeutic purposes.
RESULTS
Genome-wide RNAi Synthetic Lethal Screen against
the KRAS Oncogene
We chose the colorectal cancer cell line DLD-1 for the primary
screen (Figure 1A). These cells carry an endogenous activating
KRAS G13D point mutation required for maintaining their onco-
genic state (Shirasawa et al., 1993; Torrance et al., 2001). An
isogenic clone of DLD-1 cells with the KRASG13D allele disrupted
shows decreased MAP kinase signaling and reduced prolifera-
tion on adherent surfaces and is no longer able to sustain
anchorage-independent growth in vitro (Figures 1B–1D) or tumor
growth in vivo. Thus, DLD-1 cells clearly exhibit addiction to the
KRAS oncogene and their malignant phenotype critically
depends on mutant KRAS function.836 Cell 137, 835–848, May 29, 2009 ª2009 Elsevier Inc.We screened the parentalKRASWT/G13D (Ras Mut) DLD-1 cells
and the isogenic KRAS WT/ (Ras WT) DLD-1 control cells with
our library of 74,905 retroviral shRNAs targeting 32,293 unique
human transcripts (including 19,542 RefSeq transcripts). The
library was screened in 6 pools of 13,000 shRNAs per pool
using a protocol described previously (Figure 1A) (Schlabach
et al., 2008). We analyzed the change in relative abundance of
each shRNA over time by microarray hybridization to identify
those that are antiproliferative and are thus depleted from the
population. We compared the lethality signature of the Ras
Mut and WT cells to identify those shRNAs showing selective
depletion in the Ras Mut but not Ras WT cells. Such shRNAs
are potential Ras synthetic lethal (RSL) candidates. Relaxed
statistical criteria identified 1741 RSL shRNAs targeting 1613
genes, whereas a more stringent cutoff identified a subset 379
RSL shRNAs targeting 368 genes (Tables S1 and S2 available
online).
We devised a multicolor competition assay (MCA) to test the
reproducibility of candidate RSL shRNAs from the primary
screen (Smogorzewska et al., 2007). Individual shRNAs were
packaged into retroviruses and infected into a 50:50 mixture of
GFP+ DLD-1 Ras Mut cells and GFP (colorless) DLD-1 Ras
WT cells. The relative ratio of Ras Mut versus WT cells at
7 days post-shRNA infection was analyzed by FACS and
compared to that of the same cells infected with a negative
control shRNA targeting luciferase (Figure 1E). Using this assay
we tested 320 candidate RSL shRNAs from the primary screen
and found 83 shRNA (26%) targeting 77 genes to preferentially
decrease the fitness of Ras Mut cells compared to Ras WT cells
(Table S3). To rule out cell-line-specific effects, we performed
MCAs in a second isogenic pair of colorectal cancer cell lines:
HCT116 KRAS WT/G13D and HCT116 KRAS WT/, which were
derived in the same manner as the DLD-1 isogenic pair (Shira-
sawa et al., 1993; Torrance et al., 2001). Many shRNAs that
scored in the DLD-1 cells also showed synthetic lethality in the
HCT116 cells (50 of 68 tested, 73.5%, Table S3), indicating
that the majority of candidate RSL shRNAs are likely to interact
genetically with KRAS.
Functional Diversity of Candidate RSL Genes
We recovered shRNAs against KRAS itself from the screen. In
accordance with the phenotype of the Ras WT isogenic controls,
shRNA-mediated knockdown of KRAS expression (both Mut
and WT protein) in both DLD-1 and HCT116 cells resulted only
in modest decrease in growth on adhesive surfaces but severely
impaired colony formation in soft-agarose (Figure S1), thus con-
firming the inhibition of KRAS to be sufficient for suppressing the
malignant phenotype of these cells. Both the MAP kinase and PI
3-kinase pathways have been implicated in Ras-driven onco-
genesis. However, we recovered few genes in these pathways
and the MEK inhibitor U0126 and PI3K inhibitor LY294002 did
not cause selective toxicity toward Ras Mut cells compared to
Ras WT cells, indicating that inhibiting MEK or PI3K alone in
these cells is not sufficient to constitute synthetic lethality
(Figure S1) (Haigis et al., 2008).
The list of candidate RSL genes is functionally diverse
(Figure 2A and Table S3). Using PANTHER (Thomas et al.,
2003), we identified several biological processes including
protein modification, nucleic acid metabolism, cell cycle, and
signal transduction to be enriched in our screen. We also iden-
tified a number of pathways upon which Ras Mut cells are
more dependent. For example, we identified shRNAs against
genes in ribosomal biogenesis and translation control (BXDC2,
FBL, NOL5A, EIF3S8, EIF3S4, GSPT1, HNRNPC, and METAP1),
in protein neddylation (COPS3, COPS4, COPS8, NEDD8,
and NAE1/APPBP1) and sumoylation pathways (SAE1, UBA2,
andUBE2I), and in RNA splicing (FIP1L1,NXF1,USP39,DHX8, and
THOC1). While many of these are essential genes under circum-
stances of complete depletion, we have found that partially
reducing their activity leads to enhanced growth defects in Ras
Mut cells. To rule out off-target effects, we tested multiple
shRNAs against several of these genes, and in the majority of
Figure 1. Scheme of the Ras Synthetic
Lethal Screen
(A) Schematic of the primary screen. Change in
a particular shRNA’s abundance in the pool over
time is tracked by competitive hybridization
between the initial (PD 0) and final samples
(PD 17). A low Cy3/Cy5 ratio indicates the dropout
of an antiproliferative shRNA from the pool.
Synthetic lethal shRNAs are selectively depleted
from the Ras Mut cells. (PD, population doubling;
HH, half-hairpin.)
(B) MAPK pathway activity in DLD-1 cells. Phos-
phorylation on p42/p44 Erk kinases in cells that
were either in full media, serum-starved overnight,
or serum-starved and then stimulated with full
media.
(C) Growth curve of DLD-1 cells in culture.
(D) Anchorage independence colony formation of
DLD-1 cells in soft-agarose, assessed 2 weeks
after seeding.
(E) Schematic of the competition assay used to
validate shRNAs from the primary screen. Ras
Mut cells expressing GFP and Ras WT cells were
mixed and coinfected with the same retroviral
shRNA. The Mut to WT cell ratio at the end of the
experiment is measured by FACS. The percentage
ofRas Mutcells in themixture infected with a candi-
date RSL shRNA was normalized against that of
a control shRNA targeting firefly luciferase (FF).
cases we were able to identify additional
shRNAs that give the same phenotype
(Figure 2B).
These findings suggest that Ras
requires additional support from many
genes to maintain the oncogenic state.
For example, we identified the RNA pro-
cessing/export factor THOC1, a member
of the TREX mRNA transport complex,
to be synthetically lethal with Ras
(Figure 2B). THOC1 was recently shown
to be selectively required for the Ras-
driven proliferation and transformation
of murine fibroblasts (Li et al., 2007). We
also identified several subunits of the
COP9 signalosome (Cope and Deshaies,
2003), which regulates the activity of SCF ubiquitin ligases as
RSLs. Depleting either COPS3 or COPS4 impaired the fitness
of Ras Mut cells relative to Ras WT cells in the competition assay
(Figure 2). Furthermore, DLD-1 Ras Mut cells with stable deple-
tion of COPS4 exhibit impaired growth both on adherent
surfaces and in soft agarose (Figure S2).
Ras Mutant Cells Are Sensitive to Mitotic Perturbations
Strikingly, we identified a number of genes involved in the regu-
lation of mitosis as RSL genes. Among these are cyclin A2
(CCNA2), hMis18a and hMis18b (C21ORF45 andOIP5), borealin
(CDCA8), KNL-1 (CASC5), MCAK (KIF2C), subunits of the
anaphase-promoting complex/cyclosome (APC/C) complex
(ANAPC1, ANAPC4, CDC16, and CDC27), SMC4, and theCell 137, 835–848, May 29, 2009 ª2009 Elsevier Inc. 837
mitotic kinase Polo-like kinase 1 (PLK1) (Tables S1 and S3). Their
depletion phenotypes are likely to be on-target effects as
multiple shRNAs gave similar results (Figures 3A and S3A).
The identification of many mitotic genes as RSL candidates
suggests that Ras Mut cells might experience heightened mitotic
stress. Indeed, despite having a modestly faster doubling time
(Figure 1C) and a similar percentage of G2 cells relative to Ras
WT cells (26.1 ± 3.3 versus 26.7 ± 4.5), DLD-1 Ras Mut cells
show a 50% higher mitotic index, indicative of slower mitotic
progression (Figure 3B). Furthermore, when released from
a mitotic block induced by the Eg5 kinesin inhibitor monastrol
(Mayer et al., 1999), a significantly higher fraction of Ras Mut
cells exhibit lagging chromosomes in anaphase (Figure 3C). To
further explore the consequences of mitotic stress pharmaco-
logically, we examined the sensitivity of the Ras Mut and WT
cells toward two inhibitors of mitotic spindle function, nocoda-
zole and paclitaxel (Peterson and Mitchison, 2002). Whereas
both the Ras Mut and WT cells show comparable sensitivity to
the microtubule depolymerizer nocodazole (Figure S3B), both
DLD-1 and HCT116 Ras Mut cells show increased sensitivity
Figure 2. Functional Diversity of Candidate RSL
Genes
(A) Functional classification of candidate RSL genes in Table
S3 based on biological processes as annotated in PANTHER.
The p value denotes selective enrichment for genes in the cor-
responding biological process.
(B) Validation of candidate RSL genes with multiple shRNAs
using the competition assay. FF, negative control shRNA tar-
geting firefly luciferase (for each shRNA p < 0.01 compared to
the respective FF control, except cases marked with *, which
have p < 0.05; error bars indicate standard deviation).
to the microtubule stabilizer paclitaxel relative to
their respective WT counterparts (Figures 3D and
S3C). Cell-cycle analysis reveals that, at the syn-
thetic lethal concentration, paclitaxel causes a
strong G2/M arrest in Ras Mut cells but not in Ras
WT cells that is attributed to a striking prometa-
phase block in the Ras Mut cells (Figures 3E and
3F). Together these findings indicate that the Ras
oncogene causes increased mitotic stress and
renders the cell hypersensitive to perturbation of
the mitotic machinery.
Ras Mutant Cells Are Hypersensitive
to Inhibition of PLK1 Function
PLK1 plays a key role in mitosis (Barr et al., 2004;
Petronczki et al., 2008). Its activity is often deregu-
lated in cancer cells and inhibitors against PLK1
have been developed as potential cancer thera-
peutics (Strebhardt and Ullrich, 2006). We discov-
ered that multiple shRNAs against PLK1 show
increased toxicity toward Ras Mut cells compared
to Ras WT cells in both DLD-1 and HCT116
isogenic pairs (Figures 4A and S4A). Furthermore,
siRNAs against PLK1 also yielded enhanced
toxicity toward Ras Mut cells (Figure S4B).
To further confirm this, we tested the effect of BI-2536, a highly
selective small-molecule inhibitor of PLK1 (Steegmaier et al.,
2007). We observed increased sensitivity of Ras Mut cells toward
BI-2536 in both DLD-1 and HCT116 isogenic pairs (Figures 4B
and S4C), with the strongest effect found at 25 nM in DLD-1 cells.
We next analyzed cell-cycle distribution of DLD-1 cells after
treatment with either 25 nM or 50 nM of BI-2536 for 24 hr.
Whereas the cell-cycle profile of Ras WT cells is only modestly
affected, Ras Mut cells show a profound G2/M accumulation
in the presence of BI-2536 (Figure 4C). Microscopy analysis
revealed the G2/M accumulation in Ras Mut cells is due to
a strong block in prometaphase: whereas a substantial number
of metaphase and anaphase cells could still be found among
Ras WT cells in the presence of BI-2536, few such cells were
found among Ras Mut cells (Figures 4D and S4D).
PLK1 functions at multiple stages during mitosis (Petronczki
et al., 2008). To investigate whether PLK1 inhibition delays
mitotic entry in DLD-1 Ras Mut cells, we synchronized cells at
the G2/M boundary using the CDK1 inhibitor RO-3306 (Vassilev
et al., 2006) and released them with or without the presence of838 Cell 137, 835–848, May 29, 2009 ª2009 Elsevier Inc.
Figure 3. Hypersensitivity of Ras Mut Cells to Mitotic Stress
(A) Examples of mitotic genes with multiple shRNAs showing synthetic lethality with mutant Ras (for each shRNA p < 0.01 compared to the respective FF control,
except * p < 0.05 and # not significant; error bars indicate standard deviation).
(B) Mitotic index in asynchronous DLD-1 cells growing in log-phase as measured by phospho-H3 Ser10 staining (* p < 0.05; error bars indicate standard
deviation).
(C) Ras Mut DLD-1 cells show a higher frequency of abnormal anaphases (lagging chromosomes) 40 min after release from the metaphase block by monastrol
(* p < 0.05; error bars indicate standard deviation). An example of Ras Mut cell with a lagging chromosome (arrowhead) is shown.
(D) The microtubule stabilizer paclitaxel selectively decreases the fitness of Ras Mut cells in a dose-dependent fashion. The competition assay was carried out in
the presence of paclitaxel for 5 days (* p < 0.05, ** p < 0.01 compared to untreated samples; error bars indicate standard deviation).
(E) Paclitaxel preferentially induces the G2 and mitotic accumulation of Ras Mut DLD-1 cells as assessed by FACS using DNA and phospho-H3 Ser10 staining,
respectively (** p < 0.01; error bars indicate standard deviation).
(F) Paclitaxel causes strong prometaphase arrest in mitotic DLD-1 Ra Mut cells (shown are mean values of independent triplicates).BI-2536 into nocodazole to trap mitotic cells. Mitotic entry was
faster for Ras Mut cells but was unaffected by BI-2536 in either
Ras WT or Ras Mut cells (Figures 4E and S4E). We next releasedmitotic cells synchronized in nocodazole and tested their ability
to complete mitosis in the presence of BI-2536. Whereas
BI-2536 had minimal effect on Ras WT cells in this respect, itCell 137, 835–848, May 29, 2009 ª2009 Elsevier Inc. 839
Figure 4. Hypersensitivity of Ras Mut Cells to PLK1 Inhibition
(A) PLK1 depletion by shRNA leads to enhanced toxicity in Ras Mut cells (for each shRNA p < 0.01 compared to respective FF control, except * p < 0.05; error bars
indicate standard deviation).
(B) The PLK1 inhibitor BI-2536 selectively decreases the fitness of Ras Mut cells in a dose-dependent fashion. The competition assay was carried out in the
presence of BI-2536 for 5 days (* p < 0.05, ** p < 0.01 compared to untreated samples; error bars indicate standard deviation).
(C) Effect of synthetic lethal concentrations of BI-2536 on cell-cycle distribution of Ras Mut and Ras WT DLD-1 cells after 24 hr of treatment. Cell-cycle profiles
shown are representative of three experiments.
(D) BI-2536 causes strong prometaphase arrest in mitotic DLD-1 Ras Mut cells (shown are mean values of independent triplicates).
(E) BI-2536 does not differentially affect mitotic entry in DLD-1 Ras Mut and WT cells. Cells synchronized at G2/M by RO-3306 were released into nocodazole
(100 ng/ml) together with indicated concentrations of BI-2536 for 1 hr. Mitotic index was measured as the percentage of cells staining positive for phospho-H3
Ser10. NR, no release (error bars indicate standard deviation).
(F) BI-2536 differentially affects mitotic progression in DLD-1 Ras Mut and WT cells. Mitotic cells collected by nocodazole shake-off were released into indicated
concentrations of BI-2536 for 2 hr. Mitotic index was measured as above (* p < 0.05, ** p < 0.01 compared to samples without BI-2536 treatment; error bars
indicate standard deviation). NR, no release.
(G) Effect of BI-2536 (25 nM) on cell-cycle distribution of DLD-1 Ras Mut and WT cells over a 48 hr period (* p < 0.05, ** p < 0.01; error bars indicate standard
deviation).840 Cell 137, 835–848, May 29, 2009 ª2009 Elsevier Inc.
caused a profound delay in mitotic exit in Ras Mut cells (Figures
4F and S4F). This finding further supports the notion that Ras Mut
cells are more dependent upon PLK1 for mitotic progression.
The mitotic arrest of Ras Mut cells in BI-2536, however, was
not sustained over time. Prolonged treatment with BI-2536 for
48 hr results in an elevated sub-G1 population in Ras Mut cells,
indicative of cell death (Figures 4G and S4G).
PLK1 is transcriptionally upregulated in late S and in G2 phase,
whereas its catalytic activation requires phosphorylation at
Thr210 by the kinase Aurora-A at the G2/M transition (Seki
et al., 2008; Macurek et al., 2008). A simple explanation of our
results would be that Ras Mut cells had lower PLK1 protein levels
or activity during mitosis. However, the levels of both total and
activated PLK1 protein are actually slightly elevated in Ras Mut
cells during mitosis, particularly at G2/M (Figure S4H). Together
our findings suggest that activated Ras adversely affects mitotic
progression and renders cells more dependent on PLK1 activity
for proper mitotic progression.
Ras Mutant Cells Are Hypersensitive to APC/C
and Proteasome Inhibition
Mitotic progression is controlled by the activity of the APC/C,
an E3 ubiquitin ligase that promotes the orderly degradation
of key mitotic proteins (Peters, 2006). Several APC/C subunits
including APC1/ANAPC1, APC4/ANAPC4, Cdc16, and Cdc27
scored in our screen (Tables S1 and S3; Figure 5A), suggesting
that Ras Mut cells are more dependent on APC/C activity for
mitotic progression. The activity of APC/C is inhibited by EMI1
prior to mitosis, until PLK1 phosphorylates EMI1 and targets it
for degradation via the SCF-bTRCP E3 ligase (Reimann et al.,
2001; Hansen et al., 2004). The binding partner of EMI1, EVI5,
on the other hand, blocks PLK1 phosphorylation of EMI1 and
thereby antagonizes APC/C activation (Eldridge et al., 2006).
Thus if Ras Mut cells are more dependent on APC/C activity,
they might also be more sensitive to EMI1 or EVI5 overexpres-
sion. This is indeed the case. When we lentivirally overexpressed
exogenous EMI1 and EVI5 in these cells, the viability of Ras Mut
cells was specifically impaired (Figure 5B). Our results suggest
that either APC/C activation might be reduced in Ras Mut cells
or these cells show a higher dependence on normal APC/C
activity for survival. Consistent with these models, subpheno-
typic siRNA knockdown of APC/C subunits strongly synergizes
with subphenotypic low concentrations of BI-2536 to confer
synthetic lethality in DLD-1 Ras Mut cells (Figure 5C).
Two steps in the central pathway identified in our screen
require proteolysis. Both activation of the APC/C through EMI1
ubiquitination and APC/C-targeted ubiquitination of mitotic
proteins ultimately require proteasome activity for degradation.
Importantly, our screen also identified shRNAs against several
proteasome subunits including PSMA5, PSMB5, and PSMB6
(Figure 5D). Furthermore, two structurally distinct small-mole-
cule inhibitors of the proteasome, MG132 and bortezomib (Vel-
cade), both exhibit synthetic lethality with Ras Mut cells (Figures
5E and S5A). Consistent with the model that the hypersensitivity
of Ras Mut cells to proteasome inhibition is in part due to mitotic
defects, Ras Mut cells are more sensitive to MG132- and borte-
zomib-induced G2/M arrest (Figures 5F and S5B), again due to
a profound prometaphase block (Figure 5G). Interestingly, wefound that DLD-1 Ras Mut cells have higher levels of cyclin B1,
a key mitotic cyclin that must be degraded by the APC/C during
metaphase-anaphase transition (Figure S5C). Together these
results suggest that the Ras oncogene causes a heightened
dependency on the APC/C and renders cells sensitive to further
inhibition of this complex.
Mitotic Inhibitors Attenuate Tumor Xenograft
Growth In Vivo
To assess whether targeting the mitotic machinery could
inhibit the growth of Ras Mut DLD-1 and HCT116 cells in vivo
using mouse xenograft models, we treated nude mice bearing
subcutaneous DLD-1 or HCT116 tumors with the PLK1 inhibitor
BI-2536. In both cases we found tumor growth to be significantly
attenuated in animals treated with BI-2536 (Figures 6A and 6B).
In agreement with their in vitro sensitivity, we find HCT116
tumors to be more sensitive to BI-2536 compared to DLD-1
tumors.
The Mitotic Machinery as an Achilles’ Heel for Ras
Mutant Cancer Cells
Taken together, our results suggest that cancer cells with mutant
Ras experience elevated mitotic stress and are more dependent
on key mitotic proteins such as PLK1, the APC/C complex, the
COP9 signalosome, and the proteasome for proper mitotic
progression (Figure 6C), and we showed that targeting selected
mitotic proteins could exacerbate this mitotic stress to selectively
kill Ras mutant cancer cells. We have shown that small-molecule
inhibitors that disrupt mitosis, including paclitaxel, BI-2536, bor-
tezomb (Velcade), and MG132, all constitute synthetic lethality
with Ras mutant cells. Strikingly, transient treatment of DLD-1
cells for 24 hr with these drugs, which approximates the length
of one cell cycle for these cells, is sufficient to selectively impair
the viability of Ras Mut cells (Figure S6). This indicates that
many Ras Mut cells might not recover from their drug-induced
mitotic arrest and fail to complete normal mitosis following the
inhibitor removal.
To assess whether this mitotic stress might also be associated
with other oncogenes, we tested potential synthetic lethal inter-
actions between paclitaxel, BI-2536, bortezomib, or MG132 and
the PIK3CA oncogene. DLD-1 and HCT116 cells also harbor
oncogenic mutations in PIK3CA encoding the p110a catalytic
subunit of PI3K. Isogenic DLD-1 and HCT116 cell lines in which
the PIK3CA oncogene has been deleted by homologous recom-
bination have been generated (Samuels et al., 2005). In contrast
to Ras Mut DLD-1 cells, PI3K Mut DLD-1 cells are more resistant
to these inhibitors compared to PIK3CA WT DLD-1 cells.
Furthermore, HCT116 PI3K Mut and WT cells showed very little
difference when treated with these inhibitors (Figure S7). These
results indicate that the increased mitotic stress we observed
is specific for oncogeneic Ras.
Although the detailed mechanisms by which the Ras onco-
gene affects the activity of various mitotic machineries remain
to be elucidated, our data suggest that either impaired APC/C
function or an enhanced requirement for APC/C function might
be a critical oncogenic stress associated with Ras mutation.
We tested this proposition using a panel of non-small cell lung-
cancer (NSCLC) cell lines with or without Ras mutations byCell 137, 835–848, May 29, 2009 ª2009 Elsevier Inc. 841
Figure 5. Ras Mut Cells Are Hypersensitive to APC/C and Proteasome Inhibition
(A) Multiple shRNAs against APC1 and APC4 confer synthetic lethality in Ras Mut cells as measured by the competition assay (for each shRNA, p < 0.05 compared
to respective FF control, except # not significant; error bars indicate standard deviation).
(B) Overexpression of the APC/C inhibitor EMI1 and its binding protein EVI5 selectively impair the viability of Ras Mut cells (* p < 0.05 compared to uninfected
samples; error bars indicate standard deviation).
(C) siRNA-mediated knockdown of APC/C subunits synergizes with low concentration of BI-2536 to selectively impair the viability of DLD-1 Ras Mut cells
as measured by the competition assay. Cells were transfected with pools of 4 siRNAs against each gene; 2 days post-transfection cells were treated with
10 nM of BI-2536 for 3 days before analysis by FACS (* p < 0.05 compared to untransfected samples in the sample treatment group; error bars indicate standard
deviation).
(D) shRNAs targeting various proteasome subunits exhibit synthetic lethality in Ras Mut cells (for each shRNA, p < 0.05 compared to respective FF control,
except # not significant; error bars indicate standard deviation).842 Cell 137, 835–848, May 29, 2009 ª2009 Elsevier Inc.
Figure 6. A Model of Mitotic Regulation by Ras
(A) BI-2536 attenuates DLD-1 tumor growth in vivo. Intravenous injection of BI-2536 started 1 week after subcutaneous injection of DLD-1 cells. Tumor volume at
each time point was normalized to the initial tumor volume (* p < 0.05 and ** p < 0.01, two-way ANOVA, error bars indicate standard error of the mean [SEM]).
Representative images of tumors after treatment are shown.
(B) BI-2536 attenuates HCT116 tumor growth in vivo. Treatment of HCT116 xenografts was similar to that described for DLD-1 tumors (* p < 0.05 and ** p < 0.01,
two-way ANOVA, error bars indicate SEM).
(C) A model in which oncogenic Ras introduces mitotic stress that can be exacerbated to produce lethality by interfering with kinetochore and APC/C function.
Genes shaded green are RSL genes, while yellow genes cause Ras-specific lethality when overproduced. Dotted lines illustrate genetic connections between
Ras and aspects of mitotic regulation leading to mitotic stress.
(D) Sensitivity of a panel of NSCLCs to APC/C shRNAs. NSCLCs with endogenous Ras mutations (H23, H358, H647, H1299, H1734, H2030, H2122, and H460)
and without Ras mutations (H522, H838, H1437, H1650, H1838, and H1975) were infected with shRNAs against APC1 or APC4. Cell viability was compared to
control FF shRNA infected samples 6 days post-infection.assessing their sensitivity to shRNA-mediated knockdown of
either APC1 or APC4. Since these cell lines are not isogenic
and harbor many additional, different mutations, they are ex-
pected to display a range of sensitivities to APC/C knockdown.However, as a group the NSCLC cells with Ras mutations are
generally more sensitive to shRNAs against APC1 and APC4,
thereby further supporting the notion that Ras mutation is asso-
ciated with mitotic stress (Figure 6D).(E) The proteasome inhibitors MG132 and bortezomib selectively decreased the fitness of DLD-1 Ras Mut cells in a dose-dependent fashion over 4 days
(* p < 0.05,** p < 0.01 compared to untreated samples; error bars indicate standard deviation).
(F) MG132 and bortezomib preferentially induce the accumulation of Ras Mut DLD-1 cells as assessed by FACS using staining (** p < 0.01 compared to samples
without drug treatment; error bars indicate standard deviation).
(G) MG132 and bortezomib cause strong prometaphase arrest in mitotic DLD-1 Ras Mut cells (shown are mean values of independent triplicates).
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If our in vitro and mouse xenograft analyses are relevant to
Ras-driven tumors, patients bearing tumors with activated Ras
could benefit from decreased APC/C activity. Support for this
hypothesis comes from analysis of lung cancer tumor samples.
We analyzed whether the expression of any of our core mitotic
RSL candidate genes and other genes directly associated with
APC/C function (EMI1, EVI5, Cdc20, Cdh1, and UbcH10) corre-
lated with patient prognosis in a large cohort of lung cancer
samples (Shedden et al., 2008). As the mutation status of the
Ras genes in these tumors is currently unknown but their
transcriptional profiles are known, we first derived a Ras expres-
sion signature from a separate, smaller set of lung tumors whose
Ras mutation status was known (Bhattacharjee et al., 2001).
Importantly, we were able to validate the predictive power of
Figure 7. Candidate RSL Genes Associated with Pro-
gnosis in Human Lung Adenocarcinomas Showing
Activation of the Ras Pathway
(A) A gene expression signature for lung cancers with acti-
vated Ras pathway. A previously derived gene expression
signature (766 genes) of KRAS mutant versus wild-type lung
tumors was used as a probe in an additional set of expression
profiles from 442 human lung adenocarcinomas. Both tumors
with significant (p < 0.01) similarity or dissimilarity to the
KRAS signature (‘‘Ras signature +’’ and ‘‘Ras signature ’’
tumors, respectively) were considered for subsequent survival
analyses.
(B) RSL pathway genes that correlate with prognosis among
‘‘Ras signature +’’ tumors. The expression of two RSL genes,
COPS3 and CDC16, are inversely correlated with better
survival whereas expression of EVI5 correlates with better
survival (p < 0.05, both log-rank and Cox, log-rank p values
shown). Within each of the two tumor subsets considered
(‘‘Ras signature +’’ and ‘‘Ras signature ’’), tumors with
expression levels for the given gene greater than the median
(red line) were compared to the rest of the tumors in the subset
(blue line), using Kaplan-Meier analysis.
(C) Prognosis in ‘‘Ras signature +’’ and ‘‘Ras signature ’’
tumors using combined information from COPS3, CDC16,
and EVI5. For each of the three genes, ‘‘+’’ and ‘‘’’ is relative
to their median expression across the subset of tumors. Within
each of the two tumor subsets, three tumor groups were
compared by Kaplan-Meier analysis: tumors with high
CDC16, high COPS3, and low EVI5 (‘‘CDC16+ COPS3+
EVI’’); tumors with low CDC16, low COPS3, and high EVI5
(‘‘CDC16 COPS3 EVI+’’); and tumors not falling into these
two groups (‘‘other’’). Log-rank p values indicate significant
differences among any of the three groups.
our Ras signature in two additional cohorts of
lung tumor samples (Figure S8). We applied this
Ras signature to our large cohort to stratify the
samples as having positive, negative, or neutral
Ras signatures (Figure 7A). We defined 143 tumors
as having a strong Ras mutant signature (Ras
signature +) and 116 as having a WT-Ras signature
(Ras signature ). We then asked if the expression
levels of any of the 24 APC/C and COP9-associ-
ated core genes were associated with prognosis
in a manner that was also dependent on the
tumor’s Ras signature status. Three genes,
COPS3,CDC16, and EVI5, showed such a correlation. Strikingly,
lower expression of COPS3 and CDC16 and higher expression
of EVI5—all consistent with potentially decreased APC/C
activity—are each associated with enhanced survival for
patients bearing tumors with a positive Ras signature but have
no prognostic value in patients bearing tumors with a negative
Ras signature (Figure 7B). The correlation pattern of these genes
remains significant after correction for multiple hypothesis
testing (p = 0.02). When the tumors were simultaneously investi-
gated for all three genes, those with lower COPS3 and CDC16
together with higher EVI5 expression levels were associated
with a striking enhancement of survival for patients bearing
tumors that exhibit a positive Ras signature (Figure 7C). These
findings are consistent with the hypothesis that APC/C activity844 Cell 137, 835–848, May 29, 2009 ª2009 Elsevier Inc.
could present a limiting factor in Ras mutant cancer cells and
present an attractive drug target for cancers with Ras mutation.
DISCUSSION
Using our pool-based shRNA platform in a genome-wide screen,
we identified candidate RSL genes whose depletion constitutes
synthetic lethality with the KRAS oncogene. The vast majority of
these are implicated in Ras function for the first time. Our study
suggests that a broad genetic network spanning multiple cellular
functions is required to support the Ras oncogenic state. Many
genes in this network could be exploited as potential therapeutic
targets, as demonstrated by the synthetic lethal effect of their
depletion by RNAi.
Mitotic Stress as a Hallmark of the Ras Oncogenic State
We identified multiple mitotic genes whose inhibition results in
synthetic lethality with mutant Ras. These findings underscore
a previously underappreciated role for Ras in regulating mitotic
progression and suggest that the Ras oncogene renders cells
more dependent on key mitotic proteins for survival, possibly
by compromising the fidelity of mitosis itself and generating
mitotic stress. It has been shown that mutant Ras can induce
chromosome instability (Denko et al., 1994). How Ras affects
mitotic progression is presently unclear although our data
suggest a role in regulation of prometaphase events, possibly
chromosome congression. Several reports have implicated the
Ras/MAPK pathway in mitosis. Previously, we showed that yeast
Ras genetically interacts with the kinetochore DASH/Dam1-
Duo1 complex and thus might influence spindle attachment
and resolution of syntelic attachments (Li et al., 2005). In mitotic
Xenopus oocyte extracts, MAPK activity is required for mitotic
entry and the maintenance of the mitotic state, whereas its inac-
tivation is required for mitotic exit (Wang et al., 2007; Guadagno
and Ferrell, 1998). In Xenopus oocytes arrested at metaphase of
meiosis II, a signaling pathway involving Mos-MAPK activates
Erp1/Emi2 to inhibit APC/C activation (Inoue et al., 2007; Nish-
iyama et al., 2007). Activated MAP kinase localizes to kineto-
chores (Zecevic et al., 1998) and a hyperactive MAPK pathway
can promote spindle checkpoint bypass (Eves et al., 2006). In
addition, the Ras effector, RASSF1A, has been proposed to
negatively regulate the APC/C in mammals (Whitehurst et al.,
2008). We observe that Ras activation causes a delay in mitotic
progression, lengthening it by nearly 50%. In addition, we find
that transient treatment with monastrol arrests Ras mutant cells
that upon release display a massive increase in lagging chromo-
somes during anaphase. Our data suggest that Ras mutants
are experiencing mitotic stress and exacerbating this stress in
particular ways such that interference with KNL-1, PLK1, or
MCAK or addition of paclitaxel leads to stress overload and
cell death. In support of our findings, depletion of survivin and
TPX2 has deleterious effects on Ras mutant cells (Sarthy et al.,
2007; Morgan-Lappe et al., 2007). Importantly, not all mitotic
perturbations selectively kill Ras mutants, as nocodazole treat-
ment displayed no synthetic lethality. It will be important to
precisely dissect these mitotic defects to determine how they
might best be exploited to kill Ras mutant cells.New Drug Targets for Tumors with Ras Mutations
A key goal in cancer research is the discovery of new drug targets
that will selectively impair the viability of cancer cells. Our
approach enables the rapid identification of functional vulnerabil-
ities in cancer cells for therapeutic exploitation. Based on our
genetic analysis, we have identified at least seven such enzy-
matic targets in the mitotic pathway alone, NAE1 (the E1 for
Nedd8), the COP9 signalosome (a deneddylase), PLK1, MCAK,
the APC/C, the proteasome, and possibly the SCF. Our studies
strongly suggest that inhibiting each of these enzymatic
complexes could have efficacy in selectively killing cancer cells.
Of these targets, all have some relationship to control of the
APC/C, which, along with NAE1 and the COP9 signalosome,
presents itself as a novel target in cancer cells. In support of
this, the overproduction of two inhibitors of the APC/C, EMI1
and EVI5, is also more toxic to Ras mutant cells. Furthermore,
we showed that NSCLCs with Ras mutations tend to be more
sensitive to APC/C knockdown. Thus, inhibiting APC/C function
could prove efficacious in treating Ras-driven tumors of diverse
genetic backgrounds. In addition to mitotic regulators, our screen
has identified a functionally diverse set of RSL candidates that
have enzymatic activities and thus are potential drug candidates.
Examples are the helicase DHX8, the kinases JAK1, ERK5/
MAPK7, and RIOK1, the glutaminyl t-RNA synthase QARS, the
histone H3-K9 methyltransferase SUV39H2, the E2 SUMO-
conjugating enzyme UBA2/SAE2, and the E1 and E2 ubiquitin-
conjugating enzymes UBE1 and UBC9/UBE2I. Further validation
efforts will be needed to assess the addiction of Ras mutant cells
to these genes and determine their utility as drug targets.
Illumination of the mitotic stress phenotype of Ras mutants led
us to the identification of a number of small-molecule inhibitors
potentially useful for treating tumors with Ras mutations. Two
of these, the microtubule stabilizer paclitaxel and the proteasome
inhibitor bortezomib (Velcade), have already been approved for
the treatment of certain types of cancers. Velcade has been
approved for use in multiple myeloma (MM). Perhaps not coinci-
dentally, MM has a high frequency of Ras mutation, 30%–50% in
different studies and up to 80% in patients experiencing a relapse
(Liu et al., 1996; Bezieau et al., 2001). In addition, a significant
number of patients that do not have activating mutations in Ras
have an activated Ras pathway through IL-6 signaling (Ogata
et al., 1997; Rowley and Van Ness, 2002). Thus, the efficacy of
Velcade in treating MM might be in part due to their high preva-
lence of Ras mutations and acute activation of Ras, and it would
be important to determine if patients with Ras mutations respond
better to Velcade, thereby allowing Ras status to be used as
a marker for patient stratification in future clinical trials. The third
agent, the PLK1 inhibitor BI-2536, is currently undergoing phase I
clinical trials (Mross et al., 2008). Although their efficacy with
respect to Ras mutational status remains to be tested clinically,
finding three existing molecules as targets based on this simple
genetic screen bodes well for genetic dissection of cancers in
the future.
Additional Uses of the RSL Genes in Cancer Analysis
In addition to the discovery of novel cancer drug targets and
potential patient stratification markers for clinical trials such as
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that provide prognostic value for patient survival. Expression
levels of three genes identified in our study, COPS3, CDC16,
and EVI5, show good correlation with patient survival in the
direction that reducing APC/C activity promotes survival in
Ras-driven lung cancers but has no predictive value in lung
tumors lacking the Ras transcriptional signature. In support of
this, we found that although our Ras synthetic lethal screen
was carried out in colon cancer cells, the genetic dependency
of the Ras oncogene on the APC/C appears to be conserved
in NSCLCs as well. These findings lend strong support to the
idea that the activity of the RSL genes will affect tumorigenesis
and survival in humans. It will be interesting to see whether these
transcriptional patterns correlate with survival in other Ras-
dependent tumor types. A priori, there is no reason that these
genes in particular will correlate with survival in other cancer
types, but it is possible that other members of this RSL gene
cohort will display a similar ability in different tumor contexts
as each of them can become rate limiting for this process.
Furthermore, it is possible that other synthetic lethal cohorts
for other oncogenes or cancer types will also provide predictive
value for other tumors types.
Our study illustrates the rapidity in which synthetic lethality
analysis can be translated into better therapeutic strategies.
We find that therapeutic strategies aimed at suppressing the
Ras oncogenic pathway directly (e.g., RNAi against Ras), inhib-
iting the stress support pathways protecting the cancer cells
from oncogenic stress (e.g., RNAi and inhibitors against the pro-
teasome and the APC/C), or enhancing the stress phenotype of
cancer cells (e.g., paclitaxel) could all selectively impair the
viability of Ras mutant cancer cells. Complementary to the physi-
cal mapping of cancer genomes, functional approaches such as
these can identify genetic dependencies of cancer cells regard-
less of the mutational status of the gene of interest. Indeed, a key
point from this study is that among the many genes identified and
verified in this screen as potential drug targets, only Ras itself is
a known oncogene. This suggests that there is a much larger set
of nononcogenes that can serve as drug targets in treating
cancer. We have recently proposed the concept of ‘‘nononco-
gene addiction’’ (NOA) to describe the extensive dependency of
cancer cells on the function of diverse networks of genes—many
of which are neither mutated in cancer nor oncogenic—for their
growth and survival (Solimini et al., 2007; Luo et al., 2009). Our
study provides a glimpse of the landscape of NOA, suggests
that this is an area that is likely to shed new light on the mecha-
nisms of tumorigenesis, and presents new opportunities for
cancer therapeutics that cannot be discovered by examination
of alterations in tumors.
EXPERIMENTAL PROCEDURES
shRNA Library Screen and Micoarray Hybridization
The pool-based shRNA screen using half-hairpin (HH) barcode deconvolution
was carried out as described in Schlabach et al. (2008) at a representation of
1000, screened as 6 pools of 13,000 shRNAs per pool in independent tripli-
cates. For each pair of corresponding population doubling (PD) 0 and PD 17
samples, shRNA HH barcodes were PCR-recovered from genomic samples
and competitively hybridized to a microarray containing the corresponding
probes. Custom microarrays with HH barcode probe sequences were from
Roche Nimblegen. For additional information, see the Supplemental Data.846 Cell 137, 835–848, May 29, 2009 ª2009 Elsevier Inc.Cell Culture, Molecular Biology, and Reagents
Sequence information for additional shRNAs and siRNAs used for validation is
in Table S4. The DLD-1 and HCT116 isogenic cells were maintained in
McCoy’s 5A media supplemented with 10% FBS and antibiotics. NSCLC lines
were maintained in RPMI-1640 media with 10% FBS and antibiotics. For proli-
feration assays, cells were seeded in either 24-well or 96-well plates and cell
number was measured using CellTiterGLO (Promega). For adherent colony
assays, 1000 cells were seeded in each well of a 6-well plate and colonies
were counted 10 days later by Coomassie staining. For anchorage-indepen-
dent colony assays, 1000 cells were seeded in each well of a 6-well plate in
media containing 0.35% low-melting point agarose and colonies were
counted 3 weeks later by crystal violet staining.
Analysis of Human Lung Tumor Profiles
A gene signature of KRAS mutant versus wild-type tumors was defined, using
a published dataset of 84 lung adenocarcinomas (Bhattacharjee et al., 2001)
for which the KRAS mutation status of each tumor was known (genes with
p < 0.01, two-sided t test were selected). This KRAS signature was validated
by both gene signature similarity scores and by gene set enrichment analysis
using two independent cohorts of lung cancer where the KRAS mutation status
was known for the tumors (Ding et al., 2008; Beer et al., 2002) (Figure S8). This
KRAS gene signature was then applied to analyze a gene expression profile
dataset of 442 human lung adenocarcinomas (Shedden et al., 2008). Each
tumor was scored for manifestation of the Ras pathway as follows: The Shed-
den tumor profiles were generated among four laboratories, and so within
each laboratory subset, expression values for each gene were normalized to
standard deviations from the mean. Within each Shedden tumor profile, the
average of the genes high (‘‘up’’) in the Bhattacharjee KRAS signature were
compared with the average of the genes low (‘‘down’’) in the signature: tumors
with higher expression of the ‘‘up’’ genes as compared to the ‘‘down’’ genes
(p < 0.01, t test) were classified as showing Ras pathway manifestation
(‘‘Ras signature+’’); tumors with higher expression of the ‘‘down’’ genes (p <
0.01) were classified as not showing Ras pathway manifestation (‘‘Ras sig-
nature’’); tumors that were intermediate between the above two groups
were not used in subsequent analyses. Within the Shedden ‘‘Ras signature+’’
tumors (n = 143), tumors with expression levels greater than the median for the
given gene were compared with the rest of the tumors in the subset, using
Kaplan-Meier analysis for time to patient death. In addition, univariate Cox
analysis evaluated the expression of genes as a continuous variable for corre-
lation with outcome. The same Kaplan-Meier and Cox analyses were also
carried out using the Shedden ‘‘Ras signature’’ tumors (n = 116). To correct
for multiple hypothesis testing, we carried out simulation tests to estimate the
probability of obtaining 3 out of 24 APC/C and COP9 signalosome-associated
genes that had both a p value of <0.05 and relative expression levels that
changed in the predicted direction in KRAS mutant tumors. Based on these
criteria, the expected number of chance significant hits was 0.57 genes (based
on 1000 simulations, where both survival p value and direction of change were
randomly generated for each of the 24 genes), and the probability of getting
3 or more genes due to multiple testing was p = 0.02.
Cell-Cycle Analysis
For cell-cycle analysis, cells were analyzed using a BD LSR II FACS analyzer.
Cells were synchronization by double thymidine (Steegmaier et al., 2007) and
were released into media with the indicated drug, RO-3306 (10 mM) (Vassilev
et al., 2006), BI-2536 (Steegmaier et al., 2007), and nocodazole (100 ng/ml).
For one-step arrest in G2/M or in prometaphase, cells were treated overnight
with either RO-3306 (10 mM) or monastrol (100 mM), respectively.
Mouse Xenograft Tumor Models
DLD-1 cells (5 million cells per site) or HCT116 cells (2 million cells per site) in
suspension were mixed with equal volumes of matrigel (BD bioscience) and
injected subcutaneously into both flanks of 6-week-old female nude mice
(Charles River laboratory). Drug treatment began after 1 week of cell injection.
BI-2536 was given intravenously (i.v.) under a twice per week schedule. The
dose of BI-2536 used for DLD-1 xenografts was 50 mg/kg for the first 2 weeks
and then increased to 75 mg/kg for the last week. The dose of BI-2536 used for
HCT116 xenografts was 50 mg/kg. Measurement of tumor size was performed
twice a week, and tumor volume was estimated using the formula: volume =
Length x Width2 x 0.5. The volume of each tumor at serial time points was
normalized with the initial tumor volume and comparison of tumor volumes
between the drug treatment group and vehicle control group was carried out
using two-way ANOVA with Bonferroni post-tests.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, eight
figures, and four tables and can be found with this article online at http://
www.cell.com/supplemental/S0092-8674(09)00529-7.
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